Pertuzumab and Trastuzumab Emtansine for Human Epidermal Growth Factor Receptor-2–Positive Metastatic Breast Cancer: Contemporary Population-Based Outcomes

BACKGROUND: Real-world outcomes for patients with human epidermal growth factor receptor-2 (HER2)-positive metastatic breast cancer (MBC) treated with pertuzumab in combination with taxane chemotherapy plus trastuzumab (TaxTP) in the first line setting and trastuzumab emtansine (TE) in any line of t...

Descripción completa

Detalles Bibliográficos
Autores principales: Lupichuk, Sasha, Cheung, Winson Y, Stewart, Douglas
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2019
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6785925/
https://www.ncbi.nlm.nih.gov/pubmed/31636482
http://dx.doi.org/10.1177/1178223419879429

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6785925/
https://www.ncbi.nlm.nih.gov/pubmed/31636482
http://dx.doi.org/10.1177/1178223419879429

Ejemplares similares